Prescriptions for EpiPen alternatives such as Kaléo Inc.‘s Auvi-Q device have quadrupled since the beginning of this year, according to data from the Athenahealth Network. The demand for cheaper alternative devices is likely driven by revelations that Mylan (NSDQ:MYL) hiked the price of its EpiPen emergency allergy injector by 500% since it acquired the device in 2007.
Generic options for the injector were sparse until Kaleo’s product was re-released in mid-February this year. Mylan launched a generic version of its own device in December last year at half the price of the original and CVS said in January that it will stock Impax Laboratories‘'(NSDQ:IPXL) $10 EpiPen alternative known as Adrenaclick.
Get the full story at our sister site, Drug Delivery Business News.
The post Demand for EpiPen alternatives jumps as states consider access legislation appeared first on MassDevice.